Artivion is executing a growth strategy centered on international expansion and new product adoption, evidenced by 11.3% YoY revenue growth in Q2 2026 to $125.8M and TTM growth of 13.6%. However, the company's profitability remains strained, with operating mar...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.28-11300.0% vs $0.00 | $126M+4.8% vs $120M |
Q2 2026 May 7, 2026 | $0.03-50.0% vs $0.06 | $116M+0.6% vs $116M |
Q1 2026 Feb 12, 2026 | $0.05-63.6% vs $0.14 | $116M-0.4% vs $116M |
Q4 2025 Nov 6, 2025 | $0.16+14.3% vs $0.14 | $113M+2.7% vs $110M |
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
Benchmark AORT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Artivion, Inc. (AORT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.93 | $1.06B | 104.43 | 13.59% | 2.21% | 2.7% | — | |
| $15.92 | $1.84B | -13.05 | 8.28% | -21.25% | -44% | — | |
| $53.59 | $2.73B | -223.29 | 14.88% | 1.85% | 2.14% | — | |
| $0.66 | $46.1M | -0.57 | 15.4% | -747.19% | -94.35% | — | |
| $78.64 | $2.72B | 16.15 | 37.13% | 22.69% | 32.97% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — |
Artivion, Inc. (AORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Artivion, Inc. (AORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 18, 2026·SEC
May 15, 2026·SEC
Get notified when AORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Artivion, Inc. (AORT) stock FAQ — growth, dividends, profitability & financials explained
Artivion, Inc. (AORT) reported $471.5M in revenue for fiscal year 2025. This represents a 1174% increase from $37.0M in 1996.
Artivion, Inc. (AORT) grew revenue by 13.6% over the past year. This is steady growth.
Artivion, Inc. (AORT) reported a net loss of $3.2M for fiscal year 2025.
Artivion, Inc. (AORT) has a return on equity (ROE) of 2.7%. This is below average, suggesting room for improvement.
Artivion, Inc. (AORT) had negative free cash flow of $10.9M in fiscal year 2025, likely due to heavy capital investments.
